On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small decline. The benchmark index edged 0.15% lower to 8,831 points.

Will the market be able to bounce back from this on Tuesday? Here are five things to watch:

ASX 200 to edge lower

The Australian share market looks set for a subdued session on Tuesday despite a positive start to the week on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 8 points or 0.1% lower. In the United States, the Dow Jones rose 0.3%, the S&P 500 climbed 0.75%, and the Nasdaq stormed 1.1% higher.

Buy Genesis Minerals shares

Genesis Minerals Ltd (ASX: GMD) shares are good value according to Bell Potter. This morning, in response to a binding merger proposal with Vault Minerals Ltd (ASX: VAU), the broker has retained its buy rating on the gold miner’s shares with a trimmed price target of $9.75. It said: “The Proposed Scheme is not subject to due diligence or financing conditions and offers a materially better strategic and financial outcome than the status quo, in our view. We retain our Buy rating and lower our price target to A$9.75, on account of the recent Magnetic Resources Limited transaction completion (A$639m). The Proposed Scheme has not been incorporated pending resolution of the RRL matching right.”

Oil prices edge higher

ASX 200 energy shares including Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a positive session after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 0.05% to US$68.73 a barrel and the Brent crude oil price is up 0.05% to US$72.15 a barrel. This is despite OPEC announcing plans to boost its output.

Gold price charges higher

It could be a good session for ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) after the gold price charged higher overnight. According to CNBC, the gold futures price is up 1.2% to US$4,175.7 an ounce. Easing interest rate hike expectations boosted the precious metal.

Qantas shares on watch

Qantas Airways Ltd (ASX: QAN) shares will be worth watching on Tuesday after UK airline easyJet received a US$7.3 billion takeover offer from U.S. private equity manager Castlelake. This represents a forward multiple of approximately 16.5x estimated 2027 earnings. Qantas shares are currently trading at a deep discount of around 10x estimated FY 2027 earnings.

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• ASX 200 slips as Friday’s rally fades
• Oil price crash sparks broker upgrades for ASX energy shares
• Gold, cash, and a takeover twist: Why this ASX 200 gold stock is climbing today
• Move over Regis Resources! Vault Minerals shares leaping 11% as Genesis Minerals’ lobs $5.6 billion takeover bid

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX healthcare shares are showing renewed momentum, with two of the sector’s biggest names staging notable rebounds in recent weeks. At the time of writing, both CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) are trading higher. 

CSL shares have been one of the standout movers in the sector. The stock is up around 7% over the past five trading days and 34% over the past month, reflecting a sharp improvement in sentiment after a brutal sell-off. Despite this recovery, CSL remains heavily out of favour on a longer horizon, still down 28% year to date and nearly 49% over the past 12 months.

ResMed has also begun to recover, although its rebound has been more gradual. The ASX healthcare share is up about 10% over the past five trading days and 13% over the past month. Even so, it remains down 14% year to date and roughly 21% over the past year, leaving it well below its recent highs.

Now, the key question for investors is whether this marks the start of a sustained recovery or just a short-term bounce.

CSL: sentiment improves, but challenges remain

Earnings downgrades, acquisition concerns and a broader reset in market expectations drove the sharp decline in CSL shares. This led to a significant de-rating as investors reassessed what was once considered one of the ASX’s most reliable compounders.

The underlying business remains strong. CSL maintains its position as one of the world’s largest plasma-derived therapies companies. However, the market is now focused on whether management can restore consistent earnings momentum. Particularly as supply constraints and pricing dynamics continue to weigh on performance in key markets.

Morgans continues to support the stock. It retains a buy rating on the $58 billion ASX healthcare share with a price target of $147.59. This points to a 19% upside at current price levels.

The broker notes that the long-term story remains intact. However, a sustained recovery in sentiment may take several quarters to fully materialise as investors wait for clearer evidence in the numbers.

ResMed: growth remains intact despite volatility

The price weakness of the $44 billion ASX healthcare share has been driven more by valuation compression than by any meaningful deterioration in business performance. Broader concerns around healthcare growth stocks have also weighed on sentiment, contributing to the stock’s decline over the past year.

Despite this, the company’s fundamentals remain solid. In Q3 FY26, ResMed reported revenue rising 11% to US$1.43 billion, while non-GAAP earnings per share were up 21% to US$2.86.

Even after its recent rebound, ResMed remains at its lowest valuation level in more than a decade. It’s trading on approximately 16 times forward earnings despite expectations for double-digit earnings per share growth.

Morgans has retained a buy rating with a price target of $41.72, implying around 36% upside from current levels. The broker highlights that the current valuation may underestimate the company’s long-term growth potential.

The post 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Dexus, Resmed, BHP shares
• Down 22%! 3 reasons to buy the big dip in ResMed shares today
• 3 ASX 200 shares to buy now: experts
• Why BHP and these ASX shares could be strong buys this week
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

For retirees looking to complement their superannuation with quality investments, there are several factors to consider. 

Dividend stocks are a fantastic option because they provide passive income that can supplement retirement savings while offering the potential for long-term capital growth. 

Companies with a strong history of paying consistent, and ideally increasing, dividends can provide a reliable income stream, although it’s important to remember that dividends are not guaranteed and share prices can fluctuate. 

Another important consideration is the impact of inflation.

Many retirees will need to live off superannuation for more than 20 or 30 years, and inflation can eat into the purchasing power of their savings over time. 

Investments that have the potential to deliver returns above the rate of inflation can help preserve wealth and maintain living standards throughout retirement. 

Building a diversified portfolio that includes growth assets alongside income-producing investments can provide a balance between protecting capital and ensuring retirement savings continue to work over the long term.

Here are five options to consider that stretch across growth and income assets to compliment your superannuation. 

Dividend stocks to consider 

For retirees looking to target dividend stocks, one great option is Telstra Group Ltd (ASX: TLS). 

It is often considered an attractive dividend stock for retirees because of its established market position, relatively stable cash flows, and history of paying consistent dividends. 

Its essential telecommunications services provide resilient earnings, making it a popular choice for investors seeking reliable income alongside the potential for modest long-term capital growth.

Another dividend stock with a strong reputation is BHP Group Ltd (ASX: BHP). 

It is a popular dividend stock for retirees because of its strong balance sheet, global leadership in mining, and history of returning a significant portion of profits to shareholders through dividends. 

While dividend payments can fluctuate with commodity prices, BHP’s exposure to essential resources such as iron ore and copper provides the potential for attractive income and long-term growth.

Finally, income investors might also target Macquarie Group Ltd (ASX: MQG). 

While its dividend may be more cyclical than those of traditional defensive companies, Macquarie’s exposure to infrastructure, asset management, and renewable energy provides both income potential and opportunities for long-term capital growth.

Growth shares to consider 

While passive income is important, it isn’t the entire story for a healthy compliment to your superannuation. 

For investors looking to outpace inflation during retirements, two great ASX ETFs to consider are: 

• BetaShares Nasdaq 100 ETF (ASX: NDQ)
• Vanguard Diversified High Growth Index ETF (ASX: VDHG)

These ASX ETFs focus on strong long-term growth potential. 

This makes them both an attractive option for retirees seeking capital appreciation to help offset the effects of inflation.

They also offer broad international diversification helps reduce single-market risk while providing long-term growth potential.

The post 5 of the best investments on the ASX right now to complement your superannuation appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Dexus, Resmed, BHP shares
• Are these some of the best Betashares ETFs to buy?
• Up 57%! 3 compelling reasons to still buy BHP shares today
• Buy, hold, sell: BHP, Woodside, PLS Group shares
• Buy, hold, sell: Pro Medicus, BHP, Woolworths shares

Motley Fool contributor Aaron Bell has positions in BHP Group and BetaShares Nasdaq 100 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BetaShares Nasdaq 100 ETF and Macquarie Group. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF and Telstra Group. The Motley Fool Australia has recommended BHP Group and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.